|Printable version||E-mail this to a friend|
Cancer Research UK - Precision medicine trial first of its kind to show benefit to patients
A clinical trial for types of advanced cancer is the first of its kind to show that precision medicine – or tailoring treatment for individual people – can slow down the time it takes for a tumour to grow back, according to research presented at the Molecular Analysis for Personalised Therapy (MAP) conference(link is external), last week.
Results from the trial, which took place at the Gustave Roussy Cancer Campus(link is external) in Paris, found that 199 out of 1110 patients with advanced cancer, who had their genes mapped and their treatment tailored, had around 30 per cent longer before their cancer started growing again compared to any of the previous therapies the patients had tried. This ranged from between five and 32 months.
This trial involved patients who had no other treatment options left and who had already tried three or more cancer therapies. The team found potential faulty molecules to target for 411 of these patients and experimental drugs to hit the targets for 199 of these patients.
The patients on this trial had diverse types of advanced cancer including lung, breast, head and neck, prostate, bladder, bowel and stomach cancer.
The MAP conference is a joint initiative between Cancer Research UK, UNICANCER and ESMO.
Professor Jean Charles Soria, principal investigator of the trial from the Gustave Roussy Cancer Campus, said: “This is the first precision medicine trial to show that analysing a person’s DNA improves treatment options for patients with late stage cancer. And these results are particularly exciting because in some cases we were testing experimental drugs, and found that we could slow down the growth of tumours in around one in five patients with advanced cancer.”
Dr Christophe Massard, head of the early drug development multidisciplinary committee at Gustave Roussy, said: “The great thing about this is that it’s not just for one type of cancer - patients with many different types of cancer could benefit from this in the future.”
Dr Rowena Sharpe, head of precision medicine at Cancer Research UK, said: “This is an exciting time for precision medicine and personalised treatment. It’s fantastic to see continued effort going into this area and it’s important that we make the most of the data that we already have. The MAP meeting brings together expertise from across the globe to find the best ways to improve precision medicine programmes for cancer patients.”
For media enquiries please contact the Cancer Research UK press office on +44 203 469 8300 or, out-of-hours, the duty press officer on +44 7050 264 059.
Notes to Editor
The clinical trial is called MOSCATO 01
Latest News from
Cancer Research UK - Naturally occurring symptoms may be mistaken for tamoxifen side-effects10/12/2016 11:10:00
Women taking tamoxifen to prevent breast cancer were less likely to continue taking the drug if they suffered nausea and vomiting, according to new data presented at the San Antonio Breast Cancer Symposium (link is external)* yesterday.
BHF - Study highlights heart disease risk for pregnant women10/12/2016 10:10:00
Pregnant women and those who have recently given birth need to be aware of the symptoms of heart disease, according to a new report from researchers at the University of Oxford.
Cancer Research UK - Cancer Research Technology pioneer fund announces investment in blood cancer drugs10/12/2016 09:10:00
The Cancer Research Technology (CRT) Pioneer Fund have announced an investment to develop a promising new class of drugs for blood cancer.
Cancer Research UK - Plans for £200m NHS England cancer investment announced08/12/2016 15:35:00
Spending plans for new investment in NHS radiotherapy machines and £200m to improve local cancer services in England have been announced